/Companies

Anthology

2 known investors

Find your way into Anthology

Sign up to see every warm intro you have to Anthology

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Anthology team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Cambridge, MA biomanufacturing startup building a genome-diversification and screening platform to evolve new production organisms.

Investors · 2

Company profile

researched Aug 2026

Anthology is a Cambridge, Massachusetts-based biotechnology startup with research roots at MIT, Boston University, and Harvard. It works on biomanufacturing by accelerating the rate of genetic mutation and selection in candidate host organisms, aiming to move beyond the narrow set of simple, well-characterized organisms that current synthetic biology production relies on.

Rather than using rational modification of a few genes at a time or chemical mutagenesis producing a few point mutations, the company's techniques are described as enabling mutational capacity beyond existing scales and complexity. Anthology pairs these genome diversification tools with automated selection and screening, using proprietary hardware and custom digital tools, to identify organisms modified at the protein, pathway, and genome levels. The stated aim is to find bioproduction hosts that address expensive feedstocks, low yields, and cumbersome downstream processing.

Using the data generated by its diversification and selection work, Anthology intends to build computational and eventually constructive tools, with a longer-term vision of designing functional genomes from scratch to create novel organisms and broaden synthetic biology's product categories beyond existing high-value biomolecules, including chemicals, materials, food, enzymes, and biologics.

Founding story

Anthology was founded with roots in research at MIT, Boston University, and Harvard. Co-founder and CEO Jing Zhang has described current biomanufacturing tools as constricted and barely scratching the surface of nature's biosynthetic diversity; co-founder Tzu-Chieh (Zijay) Tang frames the company's approach as systematically creating diversity and selecting the best candidates.

▸Full profile — market position, technology, go-to-market, geography

Market position

Anthology positions itself against prevailing lab-evolution approaches in biomanufacturing, which it characterizes as constrained by a small set of well-characterized host organisms and by low-throughput diversification methods such as rational modification and chemical mutagenesis.

The company's stated differentiation is the scale of genomic diversity it can generate, combined with automated selection and screening, versus incremental gene-by-gene modification or point mutagenesis; co-founder Tzu-Chieh (Zijay) Tang compares the approach to buying a billion tickets in the genetic lottery instead of ten.

Technology

Anthology's platform combines genome diversification tools that generate large numbers of genomic variants with automated selection and screening built on proprietary hardware and custom digital tools. Its candidate host organisms are described as broader than current industry standards, and each can be further diversified to yield a wider range of potential biosynthetic factories. Selection and screening tools target modifications at the protein, pathway, and genome levels. Data from these efforts is intended to feed computational and, later, constructive genome-design tools aimed at crafting functional genomes from scratch.

Go-to-market

Biomanufacturing and synthetic biology applications spanning chemicals, materials, food, enzymes, and biologics.

Geography

Headquartered in Cambridge, Massachusetts, with origins at MIT, Boston University, and Harvard.

Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.

▸Research sources · 8

primary sources listed

8 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Anthology do?
Cambridge, MA biomanufacturing startup building a genome-diversification and screening platform to evolve new production organisms.
Who are Anthology's investors?
Anthology's investors include The Engine Ventures, Montage Ventures.